← All organizations
Highest phase reached
Phase 3
Timeline
1990s
- Jan 1, 1997
Cytokinetics— Founded
2020s
- Dec 19, 2025
aficamten— Marketing Organization
Drugs by trial phase (11 distinct, 39 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Angina Pectoris
- Atrophy
- Breast Neoplasms
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Heart Failure
- Hodgkin Disease
- Hypertrophy
- Intermittent Claudication
- Ischemia
- Lung Diseases
- Lung Diseases, Obstructive
- Lymphoma
- Lymphoma, Non-Hodgkin
- Mobility Limitation
- Motor Neuron Disease
- Muscle Weakness
- Muscular Atrophy
- Muscular Atrophy, Spinal
- Myasthenia Gravis
- Myocardial Ischemia
- Peripheral Arterial Disease
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Sclerosis
- Ventricular Dysfunction, Left
Marketed drugs (1)
Recent trials (50)
- NCT06793371OfficialPhase 2Feb 6, 2025
- NCT06793371Lead sponsorPhase 2Feb 6, 2025
- NCT06736574Lead sponsorPhase 3Dec 31, 2024
- NCT06736574OfficialPhase 3Dec 31, 2024
- NCT06412666Lead sponsorPhase 2/Phase 3May 29, 2024
- NCT06412666OfficialPhase 2/Phase 3May 29, 2024
- NCT06081894Lead sponsorPhase 3Aug 30, 2023
- NCT06081894Study directorPhase 3Aug 30, 2023
- NCT05767346Study directorPhase 3Jun 19, 2023
- NCT05767346Lead sponsorPhase 3Jun 19, 2023
- NCT05924815Study directorPhase 1May 15, 2023
- NCT05924815Lead sponsorPhase 1May 15, 2023
- NCT05877053Lead sponsorPhase 1May 9, 2023
- NCT05877053Study directorPhase 1May 9, 2023
- NCT05662215Study directorPhase 1Dec 31, 2022
Details
- Founded
- San Francisco, CA, US Jan 1, 1997
- Last known activity
- Dec 19, 2025